Successful Offering: Kodiak Sciences has successfully closed its public offering of 8 million shares, raising approximately $184 million, demonstrating strong financing capabilities in the biotechnology sector.
Enhanced Shareholder Value: The funds raised will provide ample resources to support critical Phase 3 trials for KSI-101, KSI-501, and tarcocimab, which are expected to significantly enhance the company's competitive position in the market.
Increased Market Confidence: The successful offering reflects investor confidence in Kodiak Sciences, particularly as it approaches important topline readouts for its ongoing clinical trials, which could further drive stock price appreciation.
Optimized Capital Structure: Through this offering, Kodiak Sciences showcases its disciplined approach to capital formation, aiming to enhance long-term shareholder value while securing funding for future innovations.
KOD
$26.38+Infinity%1D
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 24.17 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast KOD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 24.17 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 26.970
Low
14.00
Averages
24.17
High
40.00
Current: 26.970
Low
14.00
Averages
24.17
High
40.00
H.C. Wainwright
Matthew Caufield
Buy
maintain
$24 -> $26
2025-11-17
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$24 -> $26
2025-11-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Caufield raised the firm's price target on Kodiak Sciences to $26 from $24 and keeps a Buy rating on the shares. The firm sees a near-term catalyst for shares from the Phase 3 GLOW2 trial in reformulated tarcocimab in diabetic retinopathy patients expected Q1.
H.C. Wainwright
Matthew Caufield
Neutral -> Buy
upgrade
$5 -> $24
2025-11-11
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$5 -> $24
2025-11-11
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences to Buy from Neutral with a price target of $24, up from $5, after the company reported follow-up data from the Phase 1b APEX trial of KSI-101 in patients with macular edema secondary to inflammation. The data support continued best corrected visual acuity improvement and sustained retinal dryness, the analyst tells investors in a research note. H.C. Wainwright says its retinal work supports the prospects for KSI-101, and broader tarcocimab and KSI-501 retinal development.
JPMorgan
Neutral -> Overweight
upgrade
$15 -> $24
2025-10-24
Reason
JPMorgan
Price Target
$15 -> $24
2025-10-24
upgrade
Neutral -> Overweight
Reason
JPMorgan upgraded Kodiak Sciences to Overweight from Neutral with a price target of $24, up from $15. The firm believes the company's KSI-101 in macular edema secondary to inflammation is "de-risked" and could drive upside in the shares as the opportunity is better appreciated by the market. Data from the Phase 3 PEAK and PINNACLE studies of KSI-101 are anticipated in Q4 of 2026 and Q1 of 2027, respectively, the analyst tells investors in a research note.
LifeSci Capital
NULL
to
Outperform
initiated
$40
2025-10-23
Reason
LifeSci Capital
Price Target
$40
2025-10-23
initiated
NULL
to
Outperform
Reason
LifeSci Capital initiated coverage of Kodiak Sciences with an Outperform rating and $40 price target.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
